-

Half-year Liquidity Contract Statement for MEDINCELL

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between MEDINCELL (Paris:MEDCL) and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:

- 16,161 shares

- € 314,681.05

- Number of executions on buy side on semester: 627

- Number of executions on sell side on semester: 708

- Traded volume on buy side on semester: 66,789 shares for € 624,998.07

- Traded volume on sell side on semester: 69,983 shares for € 669,428.60

As a reminder :

• the following resources appeared on the last half year statement on 30 June 2021 on the liquidity account:

- 19,355 shares

- € 270,935.67

- Number of executions on buy side on semester: 706

- Number of executions on sell side on semester: 705

- Traded volume on buy side on semester: 76,603 shares for € 926,491.56

- Traded volume on sell side on semester: 75,802 shares for € 958,751.11

• the following resources appeared on the liquidity account when the activity started:

- 0 shares

- € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

o0o

 

Buy Side    

 

Sell Side    

 

Number of
executions

Number of
shares

Traded volume
in EUR

 

Number of
executions

Number of
shares

Traded volume
in EUR

Total

627

66,789

624,998.07

 

708

69,983

669,428.60

01/07/2021

5

600

5,490.00

 

-

-

-

02/07/2021

5

201

1,829.10

 

2

201

1,869.30

07/07/2021

1

200

1,800.00

 

-

-

-

08/07/2021

7

600

5,280.00

 

-

-

-

09/07/2021

-

-

-

 

2

207

1,863.00

12/07/2021

-

-

-

 

2

117

1,057.68

14/07/2021

1

200

1,760.00

 

1

76

687.04

15/07/2021

-

-

-

 

5

400

3,620.00

20/07/2021

5

700

6,202.00

 

-

-

-

26/07/2021

10

400

3,620.00

 

-

-

-

27/07/2021

10

182

1,667.12

 

7

600

5,520.00

28/07/2021

1

18

164.88

 

3

400

3,740.00

29/07/2021

2

395

3,732.75

 

7

436

4,163.80

30/07/2021

7

606

5,641.86

 

6

207

1,966.50

02/08/2021

9

800

7,360.00

 

4

377

3,524.95

03/08/2021

3

400

3,580.00

 

1

1

9.00

04/08/2021

1

200

1,760.00

 

9

305

2,735.85

05/08/2021

1

200

1,788.00

 

4

294

2,648.94

06/08/2021

-

-

-

 

5

600

5,472.00

09/08/2021

5

600

5,430.00

 

2

400

3,632.00

10/08/2021

4

347

3,129.94

 

3

200

1,820.00

11/08/2021

3

253

2,277.00

 

8

600

5,478.00

12/08/2021

11

400

3,628.00

 

3

200

1,820.00

13/08/2021

4

260

2,347.80

 

-

-

-

16/08/2021

8

341

3,075.82

 

7

601

5,469.10

17/08/2021

1

1

9.12

 

1

1

9.12

18/08/2021

3

401

3,693.21

 

10

801

7,393.23

19/08/2021

6

800

7,248.00

 

3

44

399.52

20/08/2021

1

1

9.07

 

2

21

190.68

23/08/2021

-

-

-

 

13

936

8,583.12

24/08/2021

4

600

5,430.00

 

4

200

1,840.00

25/08/2021

1

1

9.14

 

1

1

9.14

27/08/2021

1

200

1,808.00

 

1

2

18.40

30/08/2021

4

400

3,740.00

 

34

4,355

42,461.25

31/08/2021

-

-

-

 

1

41

430.50

01/09/2021

3

600

6,282.00

 

10

1,759

19,296.23

02/09/2021

6

800

8,200.00

 

-

-

-

03/09/2021

3

307

3,152.89

 

6

601

6,250.40

06/09/2021

17

2,019

20,028.48

 

5

800

8,104.00

07/09/2021

3

475

4,621.75

 

2

128

1,267.20

08/09/2021

-

-

-

 

2

20

198.00

09/09/2021

13

1,400

13,356.00

 

10

652

6,291.80

10/09/2021

11

600

5,694.00

 

-

-

-

13/09/2021

6

800

7,448.00

 

1

200

1,880.00

14/09/2021

1

200

1,848.00

 

-

-

-

16/09/2021

-

-

-

 

9

1,000

9,500.00

17/09/2021

29

3,072

29,061.12

 

8

1,600

15,664.00

20/09/2021

14

1,328

11,872.32

 

2

400

3,592.00

21/09/2021

-

-

-

 

5

368

3,341.44

22/09/2021

-

-

-

 

24

2,032

19,222.72

23/09/2021

10

1,200

11,304.00

 

5

600

5,826.00

24/09/2021

6

600

5,514.00

 

1

2

19.00

27/09/2021

3

401

3,637.07

 

3

11

102.96

28/09/2021

3

600

5,370.00

 

-

-

-

29/09/2021

3

317

2,799.11

 

-

-

-

30/09/2021

11

1,353

11,662.86

 

-

-

-

01/10/2021

2

330

2,778.60

 

1

161

1,400.70

04/10/2021

-

-

-

 

1

27

229.77

05/10/2021

-

-

-

 

5

400

3,472.00

07/10/2021

1

200

1,700.00

 

-

-

-

08/10/2021

1

42

354.48

 

-

-

-

11/10/2021

13

1,958

16,094.76

 

5

400

3,308.00

12/10/2021

-

-

-

 

2

200

1,660.00

13/10/2021

-

-

-

 

17

2,000

17,160.00

14/10/2021

3

102

877.20

 

2

143

1,266.98

15/10/2021

1

1

8.85

 

1

1

8.85

18/10/2021

14

1,299

10,937.58

 

-

-

-

20/10/2021

1

200

1,648.00

 

-

-

-

21/10/2021

-

-

-

 

18

2,058

17,863.44

22/10/2021

6

800

7,160.00

 

12

1,079

9,786.53

25/10/2021

-

-

-

 

28

2,433

22,675.56

26/10/2021

22

2,200

20,504.00

 

6

989

9,642.75

27/10/2021

-

-

-

 

44

4,200

39,732.00

28/10/2021

1

200

1,952.00

 

25

2,400

23,832.00

29/10/2021

18

2,400

22,896.00

 

-

-

-

01/11/2021

20

2,200

21,648.00

 

23

3,200

32,416.00

02/11/2021

24

3,200

30,656.00

 

7

800

7,864.00

03/11/2021

17

2,001

18,949.47

 

19

2,200

21,076.00

04/11/2021

15

2,041

18,899.66

 

14

1,244

11,606.52

05/11/2021

14

1,671

15,172.68

 

8

1,149

10,524.84

08/11/2021

4

552

5,061.84

 

10

808

7,562.88

09/11/2021

2

135

1,247.40

 

5

799

7,478.64

10/11/2021

-

-

-

 

17

2,200

21,230.00

11/11/2021

-

-

-

 

7

1,200

12,096.00

12/11/2021

5

600

6,090.00

 

17

1,000

10,360.00

15/11/2021

11

1,000

10,040.00

 

3

400

4,160.00

16/11/2021

-

-

-

 

2

200

2,040.00

18/11/2021

2

400

3,968.00

 

-

-

-

19/11/2021

7

600

5,874.00

 

-

-

-

23/11/2021

10

1,000

9,620.00

 

-

-

-

24/11/2021

13

1,200

11,364.00

 

2

293

2,783.50

25/11/2021

3

200

1,880.00

 

1

107

1,016.50

26/11/2021

7

674

6,241.24

 

1

200

1,912.00

29/11/2021

-

-

-

 

9

1,000

9,640.00

30/11/2021

3

200

1,900.00

 

1

1

9.56

01/12/2021

-

-

-

 

3

5

47.80

02/12/2021

9

1,000

9,740.00

 

21

1,994

19,640.90

03/12/2021

10

1,000

9,580.00

 

1

200

1,960.00

06/12/2021

-

-

-

 

13

1,200

11,688.00

07/12/2021

12

1,180

11,469.60

 

6

800

7,824.00

08/12/2021

7

1,015

9,703.40

 

-

-

-

09/12/2021

13

1,401

13,183.41

 

7

400

3,792.00

10/12/2021

6

399

3,750.60

 

4

218

2,062.28

13/12/2021

2

300

2,859.00

 

9

982

9,417.38

14/12/2021

3

600

5,670.00

 

6

600

5,742.00

15/12/2021

16

1,201

11,253.37

 

2

2

18.96

16/12/2021

2

105

966.00

 

3

401

3,781.43

17/12/2021

-

-

-

 

1

6

57.00

20/12/2021

7

800

7,536.00

 

9

933

8,891.49

21/12/2021

1

200

1,880.00

 

4

400

3,792.00

22/12/2021

1

1

9.44

 

19

1,600

15,488.00

23/12/2021

6

800

7,680.00

 

3

400

3,852.00

24/12/2021

2

201

1,917.54

 

2

201

1,929.60

27/12/2021

8

1,200

11,508.00

 

10

801

7,793.73

28/12/2021

7

600

5,760.00

 

8

639

6,172.74

29/12/2021

6

800

7,728.00

 

3

400

3,904.00

30/12/2021

3

201

1,917.54

 

4

344

3,309.28

31/12/2021

-

-

-

 

13

1,368

13,461.12

MEDINCELL

Public limited company with a capital of € 221 683.48
Registered office: 3 rue des Frères Lumière 34830 Jacou
444 606 750 R.C.S. on the Montpellier Trade and Companies Register

Contacts

MEDINCELL

MEDINCELL

BOURSE:MEDCL

Release Versions

Contacts

MEDINCELL

More News From MEDINCELL

Medincell’s ISS ESG Corporate Rating Upgraded

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announces that ISS has upgraded the company’s ESG rating from C+ to B. Medincell is ranked within the first decile of the Pharmaceuticals & Biotechnology sector, benefits from ISS ESG Prime Status, and achieves a very high level of ESG disclosure transparency. This updated rating is...

Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell’s (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and full‑year 2025 results: About UZEDY® 2025 net sales reached $191 million, including $55 million in the fourth quarter Teva’s initial 2026 net sales outlook is in the range of $250 - $280 million Medincell receives mid‑to high‑single-digit royalties on UZEDY® net sales and is eligible for up to $105...

Medincell: Half-year Liquidity Contract Statement

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at December 31, 2025: 980 shares 1 159 804 € Over the period from 01/07/2025 to 31/12/2025, a total of: Number of executions Number of shares Traded volume in EUR Buy side 13,642 1,007,509 25,098,637.27 Sell side 14,870 1,011,529 25,113,263.98 It should be noted that Medincell increase...
Back to Newsroom